Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy

American Journal of the Medical Sciences

Volumn 342, Issue 2, 2011, Pages 135-142

  Mitra, Sona ^a   Deshmukh, Abhishek ^a   Sachdeva, Rajesh ^a   Lu, Jingjun ^a   Mehta, Jawahar L ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Atherogenesis; Atherosclerosis; LDL cholesterol; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANTIOXIDANT; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; URIC ACID;

ANTIBODY BLOOD LEVEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBROBLAST; FIBROSIS; HEART PROTECTION; HUMAN; INTERNALIZATION; LIPID PEROXIDATION; MACROPHAGE; MOLECULAR INTERACTION; MONOCYTE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SMOOTH MUSCLE FIBER; THROMBOCYTE;

EID: 79961025356     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318224a147     Document Type: Conference Paper

References (92)

1. Tyroler HA. Coronary heart disease epidemiology in the 21st century. Epidemiol Rev 2000;22:7-13. (Pubitemid 30627519)
2. Ehara S, Ueda M, Naruko T, et al. Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases. J Diabetes Complications 2002;16:60-4. (Pubitemid 34168503)
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
4. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998;141:1-15. (Pubitemid 28539412)
5. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313. (Pubitemid 46209993)
6. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res 2007;100:460-73. (Pubitemid 46673256)
7. Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 2004;36:363-75. (Pubitemid 38802492)
8. Funk CD. Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26: 1204-6. (Pubitemid 44305362)
9. Lee CR, North KE, Bray MS, et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008;83:52-60.
10. Chevrier I, Tregouet DA, Massonnet-Castel S, et al. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis? Atherosclerosis 2006;188: 150-4. (Pubitemid 44142532)
11. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 2008;18:20-5.
12. Gielis JF, Lin JY, Wingler K, et al. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med 2011; 50:765-76.
13. Ananyeva NM, Tjurmin AV, Berliner JA, et al. Oxidized LDL mediates the release of fibroblast growth factor-1. Arterioscl Thromb Vasc Biol 1997;17:445-53. (Pubitemid 27133133)
14. Li D, Liu L, Chen H, et al. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-7. (Pubitemid 36176813)
15. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
16. Mehta JL, Li DY. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 1998;248:511-4. (Pubitemid 28404451)
17. Li D, Saldeen T, Romeo F, et al. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000;102:1970-6.
18. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000; 20:1116-22. (Pubitemid 30207591)
19. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101:2889-95. (Pubitemid 30415877)
20. Chen H, Li D, Saldeen T, et al. Transforming growth factor-beta(1) modulates oxidatively modified LDL-induced expression of adhesion molecules: role of LOX-1. Circ Res 2001;89:1155-60. (Pubitemid 34627873)
21. Li D, Liu L, Chen H, et al. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:816-21. (Pubitemid 36566171)
22. Roy Chowdhury SK, Sangle GV, Xie X, et al. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab 2010;298:E89-98.
23. Cominacini L, Rigoni A, Pasini AF, et al. The binding of oxidized low density lipoprotein (oxLDL) to oxLDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001;276:13750-5.
24. Dandapat A, Hu C, Sun L, et al. Small concentrations of ox-LDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb Vasc Biol 2007;27:2435-42. (Pubitemid 350203961)
25. Pataki M, Lusztig G, Robenek H. Endocytosis of oxidized LDL and reversibility of migration inhibition in macrophage-derived foam cells in vitro. A mechanism for atherosclerosis regression? Arterioscler Thromb 1992;12:936-44.
26. Yang X, Galeano NF, Szabolcs M, et al. Oxidized low density lipoproteins alter macrophage lipid uptake, apoptosis, and viability and nitric oxide synthesis. J Nutr 1996;126:10272s-5s.
27. Han J, Hajjar DP, Febbraio M, et al. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 1997;272:21654-9. (Pubitemid 27374044)
28. Draude G, Hrboticky N, Lorenz RL. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 1999;57:383-6. (Pubitemid 29065286)
29. Shen CM, Mao SJ, Huang GS, et al. Stimulation of smooth muscle cell proliferation by ox-LDL-and acetyl LDL-induced macrophagederived foam cells. Life Sci 2001;70:443-52. (Pubitemid 34017538)
30. Chai YC, Binion DG, Macklis R, et al. Smooth muscle cell proliferation induced by oxidized LDL-borne lysophosphatidylcholine. Evidence for FGF-2 release from cells not extracellular matrix. Vascul Pharmacol 2002;38:229-37. (Pubitemid 36398268)
31. Chisolm GM III, Chai Y. Regulation of cell growth by oxidized LDL. Free Radic Biol Med 2000;28:1697-707. (Pubitemid 30628656)
32. Nishio E, Arimura S, Watanabe Y. Oxidized LDL induces apoptosis in cultured smooth muscle cells: a possible role for 7-ketocholesterol. Biochem Biophys Res Commun 1996;223:413-8. (Pubitemid 26245581)
33. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007;5:265-82. (Pubitemid 46488141)
34. Marwali MR, Hu CP, Mohandas B, et al. Modulation of ADPinduced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther 2007; 322:1324-32. (Pubitemid 47295783)
35. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928-31.
36. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-60. (Pubitemid 32322222)
37. Yamashita H, Ehara S, Yoshiyama M, et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J 2007;71:681-7. (Pubitemid 46683357)
38. Mehta JL. The role of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein in atherosclerosis. Can J Cardiol 2004;Suppl B:32B-6B.
39. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7. (Pubitemid 27130922)
40. Chen M, Kakutani M, Naruko T. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun 2001;282:153-8. (Pubitemid 32924358)
41. Kataoka H, Kume N, Miyamoto S. Oxidized LDL modulates Bax/Bcl-2 through the lectin-like Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:955-60. (Pubitemid 34168652)
42. Yoshida H, Kondratenko N, Green S. Identification of the lectin-like receptor of oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J 1998;334:9-13. (Pubitemid 28420964)
43. Yamamoto N, Toyoda M, Abe M, et al. Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy. Intern Med 2009;8: 189-94.
44. Schwarz DA, Barry G, Mackay KB, et al. Identification of differentially expressed genes induced by transient ischemic stroke. Brain Res Mol Brain Res 2002;101:12-22. (Pubitemid 34467023)
45. Jono T, Miyazaki A, Nagai R, et al. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002;11:170-4. (Pubitemid 34127844)
46. Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999;84:1043-9. (Pubitemid 29227683)
47. Murase T, Kume N, Korenaga R, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;83:328-33. (Pubitemid 28371323)
48. Chen M, Kakutani M, Minami M. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:1107-15. (Pubitemid 30207590)
49. Nagase M, Hirose S, Sawamura T, et al. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun 1997;237:496-8. (Pubitemid 27434712)
50. Kataoka H, Miyamoto S. Expression of lectin-like oxidized lowdensity lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999;99:3110-7. (Pubitemid 29289075)
51. Mehta JL, Sanada N, Hu CP, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007;100:1634-42. (Pubitemid 46897266)
52. Timmermans PB, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;15:79-87.
53. Galle J, Heermeier K. Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress. Nephrol Dial Transplant 1999;14: 2585-9. (Pubitemid 32208367)
54. Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-51. (Pubitemid 30151676)
55. Li D, Yang B, Philips MI, et al. Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am J Physiol 1999;276:H786-92. (Pubitemid 29157449)
56. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22: 1257-66. (Pubitemid 34875734)
57. Zhang F, Hu Y, Xu Q, et al. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010;5:e12323.
58. Chen K, Mehta JL, Li D, et al. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004;95:1167-73. (Pubitemid 39648207)
59. Chen K, Chen J, Li D, et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 2004;44:655-61. (Pubitemid 39435235)
60. López-Farré A, Sánchez de Miguel L, Montón M, et al. Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 2001;1:45-9. (Pubitemid 32492504)
61. Feolde E, Vigne P, Frelin C. Angiotensin II receptor subtypes and biological response in the rat heart. J Mol Cell Cardiol 1993;25: 1359-67. (Pubitemid 24003842)
62. Li D, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102:1970-6.
63. Hu C, Dandapat A, Mehta JL. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redoxsensitive pathway. Hypertension 2007;50:952-7. (Pubitemid 350287540)
64. Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized lowdensity lipoprotein. Circulation 1999;100:899-902. (Pubitemid 29407168)
65. Chen J, Li D, Schaefer R, et al. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006;184:295-301. (Pubitemid 43049713)
66. Langheinrich AC, Michniewicz A, Sedding DG, et al. Correlation of vasa vasorum neovascularization and plaque progression in aortas of apolipoprotein E(-/-)/low-density lipoprotein(-/-) double knockout mice. Arterioscler Thromb Vasc Biol 2006;26:347-52. (Pubitemid 43732198)
67. Tenaglia AN, Peters KG, Sketch MH Jr, et al. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998;135:10-4. (Pubitemid 28073052)
68. Kwon HM, Sangiorgi G, Ritman EL, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998;101:1551-6. (Pubitemid 28198482)
69. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110: 2032-8. (Pubitemid 39331918)
70. Chen J, Mehta JL, Haider N, et al. Role of caspases in ox-LDLinduced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004;94:370-6. (Pubitemid 38240729)
71. Li D, Yang B, Philips MI, et al. Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am J Physiol 1999;276:H786-92. (Pubitemid 29157449)
72. Li D, Tomson K, Yang B, et al. Modulation of constitutive nitric oxide synthase, bcl-2 and Fas expression in cultured human coronary endothelial cells exposed to anoxia-reoxygenation and angiotensin II: role of AT1 receptor activation. Cardiovasc Res 1999;1:109-15. (Pubitemid 29016050)
73. Kang BY, Wang W, Palade P, et al. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 2009;54:327-34.
74. Clopath P. The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine. Br J Exp Pathol 1980;1: 440-3. (Pubitemid 10024407)
75. Surekha RH, Srikanth BB, Jharna P, et al. Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med J 2007;48: 137-42. (Pubitemid 351229415)
76. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 2010;34: 5-14.
77. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-88.
78. Wu T, Willett WC, Rifai N, et al. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol 2006;48:973-9. (Pubitemid 44292442)
79. Chen HW, Kuo CL, Huang CS, et al. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology 2008;110:252-9.
80. Förstermann U, Mügge A, Alheid U, et al. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988;62:185-90. (Pubitemid 18041940)
81. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990;81:1586-93. (Pubitemid 20158298)
82. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
83. Lind L. Arterial compliance and endothelium-dependent vasodilation are independently related to coronary risk in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Clin Physiol Funct Imaging 2008;28:373-7.
84. Kume N, Mitsuoka H, Hayashida K, et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome-comparison with other biomarkers. J Cardiol 2010;56:159-65.
85. Mehta JL, Szwedo J. Circulating endothelial progenitor cells, microparticles and vascular disease. J Hypertens 2010;28:1611-3.
86. Patel PB, Pfau SE, Cleman MW, et al. Comparison of coronary artery specific leukocyte-platelet conjugate formation in unstable versus stable angina pectoris. Am J Cardiol 2004;93:410-3. (Pubitemid 38221346)
87. Culotta VC. Superoxide dismutase, oxidative stress, and cell metabolism. Curr Top Cell Regul 2000;6:117-32.
88. Lin SJ, Shyue SK, Shih MC, et al. Superoxide dismutase and catalase inhibit oxidized low-density lipoprotein-induced human aortic smooth muscle cell proliferation: role of cell-cycle regulation, mitogen-activated protein kinases, and transcription factors. Atherosclerosis 2007; 190:124-34.
89. Lewis P, Stefanovic N, Pete J, et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 2007;115:2178-87. (Pubitemid 46659070)
90. Lin MS, Hsu HC, Lin LC, et al. Higher glutathione peroxidase expression in thoracic aorta as a protective factor against oxidative stress and atherosclerosis in rabbits. Cardiology 2007;108:381-6.
91. Lonn E, Bosch J, Yusuf S, et al; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-47. (Pubitemid 40381486)
92. Jialal I, Devaraj S. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 2000;342:154-60.